Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
conference banner
Abstract

Background: Metabolic syndrome (MetS) is characterized by insulin resistance, high blood pressure/ sugar, dyslipidemia, and obesity. Whether MetS and its components affect the development of Behçet's Disease (BD) remains unclear.

Aims: The aim was to determine the frequency of MetS among BD patients and to study its relationship with disease characteristics.

Methods: The study included 1028 adult BD patients recruited from 18 specialized rheumatology centers. 51 healthy matched control were considered. Behçet Disease Current Activity Form (BDCAF) and the BD damage index (BDI) were estimated. Adult Treatment Panel-III criteria were used to define MetS.

Results: The mean age of patients was 36.8 ± 10.1 years, M:F 2.7:1 and disease duration 7.01 ± 5.2 years. Their mean BDCAF was 5.1 ± 4.6 and BDI 5.5 ± 2.8. MetS was present in 22.8% of patients and in 5.9% of control (3.9 fold higher-risk). Patients with MetS had a significantly increased age at onset (31.8 ± 9.2 vs. 29 ± 8.5 years) and higher frequency of genital ulcers (96.2% vs. 79.7%), skin involvement (73.1% vs. 50.4%), arthritis (48.3% vs. 29.1%) (p<0.0001) and CNS manifestations (18.8% vs. 13%) (p=0.042) compared to those without it. Eye involvement was significantly increased in those with MetS (82.1% vs. 74.2%) (p=0.003) with increased frequency of posterior uveitis (67.1% vs. 43.5%), retinal vessel occlusion (35.9% vs. 21.3%), retinal vasculitis (41.9% vs. 26.4%) (p<0.0001) and vitritis (37.2% vs. 24%) (p=0.001). BDCAF was significantly lower (3.9 ± 4.3 vs. 5.6 ± 4.6) and BDI higher (7.4 ± 2.7vs5 ± 2.6) (p<0.0001).

Conclusion: BD patients with MetS are predisposed to mucocutaneous, musculoskeletal, neuropsychiatric and ocular manifestations with consequently increased damage. The involvement of the deeper structures of the eye should alarm rheumatologists to keep in mind that all patients should have an eye examination, especially those with MetS.

Keywords: Metabolic syndrome, Behçets disease, eye, neuropsychiatric, BDI.

« Previous Next »
[1]
Santarsiero A, Leccese P, Convertini P, et al. New insights into Behçet’s syndrome metabolic reprogramming: Citrate pathway dysregulation. Mediators Inflamm 2018; 2018: 1-8.
[http://dx.doi.org/10.1155/2018/1419352] [PMID: 30050389]
[2]
Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol 2017; 13(1): 57-65.
[http://dx.doi.org/10.1080/1744666X.2016.1205486] [PMID: 27351485]
[3]
Gheita TA, El-Latif EA, El-Gazzar II, et al. Behçet’s disease in Egypt: A multicenter nationwide study on 1526 adult patients and review of the literature. Clin Rheumatol 2019; 38(9): 2565-75.
[http://dx.doi.org/10.1007/s10067-019-04570-w] [PMID: 31119493]
[4]
de Menthon M, LaValley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behçet’s disease: A systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009; 61(10): 1287-96.
[http://dx.doi.org/10.1002/art.24642] [PMID: 19790126]
[5]
Travis SPL, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet’s syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001; 49(5): 725-8.
[http://dx.doi.org/10.1136/gut.49.5.725] [PMID: 11600479]
[6]
Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018; 17(1): 122.
[http://dx.doi.org/10.1186/s12933-018-0762-4] [PMID: 30170598]
[7]
Owlia MB, Mehrpoor G. Behcet’s disease: New concepts in cardiovascular involvements and future direction for treatment. ISRN Pharmacol 2012; 2012: 1-13.
[http://dx.doi.org/10.5402/2012/760484] [PMID: 22530146]
[8]
Olufadi R, Byrne CD. Clinical and laboratory diagnosis of the metabolic syndrome. J Clin Pathol 2007; 61(6): 697-706.
[http://dx.doi.org/10.1136/jcp.2007.048363] [PMID: 18505888]
[9]
Hernandez-Baixauli J, Quesada-Vázquez S, Mariné-Casadó R, et al. Detection of early disease risk factors associated with metabolic syndrome: A new era with the NMR metabolomics assessment. Nutrients 2020; 12(3): 806.
[http://dx.doi.org/10.3390/nu12030806] [PMID: 32197513]
[10]
Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008; 94(2): 206-18.
[http://dx.doi.org/10.1016/j.physbeh.2007.10.010] [PMID: 18037457]
[11]
Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: A culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27(11): 2276-83.
[http://dx.doi.org/10.1161/ATVBAHA.107.147835] [PMID: 17823366]
[12]
Prasad H, Ryan DA, Celzo MF, Stapleton D. Metabolic syndrome: Definition and therapeutic implications. Postgrad Med 2012; 124(1): 21-30.
[http://dx.doi.org/10.3810/pgm.2012.01.2514] [PMID: 22314111]
[13]
Yalçın B, Gür G, Artüz F, Allı N. Prevalence of metabolic syndrome in Behçet disease: A case-control study in Turkey. Am J Clin Dermatol 2013; 14(5): 421-5.
[http://dx.doi.org/10.1007/s40257-013-0034-8] [PMID: 23760648]
[14]
El-Gazzar I, El-Dakrony AH, Sayed S, et al. Clinical significance of metabolic syndrome and carotid intima-media thickness in Behҫet’s disease patients: Relation to disease activity. Egypt Rheumatol 2017; 39(3): 171-4.
[http://dx.doi.org/10.1016/j.ejr.2016.11.001]
[15]
Mendrick DL, Diehl AM, Topor LS, et al. Metabolic syndrome and associated diseases: From the bench to the clinic. Toxicol Sci 2018; 162(1): 36-42.
[http://dx.doi.org/10.1093/toxsci/kfx233] [PMID: 29106690]
[16]
Davatchi F, Assaad-Khalil S, Calamia KT, et al. The International Criteria for Behçet’s Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28(3): 338-47.
[http://dx.doi.org/10.1111/jdv.12107] [PMID: 23441863]
[17]
Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet’s disease: Evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38(8): 728-33.
[http://dx.doi.org/10.1093/rheumatology/38.8.728] [PMID: 10501420]
[18]
Gheita TA, Hammam N, Fawzy SM, et al. Development and validation of a Behçet’s disease damage index for adults with BD: An Explicit, Composite and Rated (ECR) tool. Int J Rheum Dis 2021; 24(8): 1071-9.
[http://dx.doi.org/10.1111/1756-185X.14166] [PMID: 34288457]
[19]
Evaluation, and treatment of high blood cholesterol in adults. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
[http://dx.doi.org/10.1001/jama.285.19.2486] [PMID: 11368702]
[20]
Lauria MW, Moreira LMP, Machado-Coelho GLL, Neto RMN, Soares MMS, Ramos AV. Ability of body mass index to predict abnormal waist circumference: Receiving operating characteristics analysis. Diabetol Metab Syndr 2013; 5(1): 74.
[http://dx.doi.org/10.1186/1758-5996-5-74] [PMID: 24252564]
[21]
Lee J, Yoo S, Han KD, et al. Association between metabolic syndrome and Behçet’s disease: A nationwide population‐based study. J Dermatol 2021; 48(7): 1062-6.
[http://dx.doi.org/10.1111/1346-8138.15809] [PMID: 33961305]
[22]
Messedi M, Naifar M, Grayaa S, et al. Plasma saturated and monounsaturated fatty acids in Behçet’s disease. Open Rheumatol J 2018; 12(1): 139-51.
[http://dx.doi.org/10.2174/1874312901812010139] [PMID: 30258503]
[23]
Pancar GS, Kalkan G. Diagnostic value of HbA1c level in Behcet’s disease and evaluation of neutrophil-lymphocyte ratio, mean platelet volume and body mass index. J Hematol (Brossard) 2015; 4(4): 219-22.
[http://dx.doi.org/10.14740/jh230e]
[24]
Kim SK, Choe JY, Park SH, Lee SW, Lee GH, Chung WT. Increased insulin resistance and serum resistin in Korean patients with Behçet’s disease. Arch Med Res 2010; 41(4): 269-74.
[http://dx.doi.org/10.1016/j.arcmed.2010.05.008] [PMID: 20637370]
[25]
Hahn HJ, Kwak SG, Kim DK, Kim JY. Association of Behçet disease with psoriasis and psoriatic arthritis. Sci Rep 2021; 11(1): 2531.
[http://dx.doi.org/10.1038/s41598-021-81972-4] [PMID: 33510251]
[26]
Demir B, Cicek D, Aydin S, Dogan FB, Erden I, Ucak H, et al. Relationship between metabolic syndrome and serum hepcidin level in patients with behcet’s disease. Glob Dermatol 2015; 2(2): 99-102.
[27]
Agirgol S, Cakir E, Gumus A, et al. Evaluation of the relationship between Behcet’s disease and cardiovascular disorders through metabolic function and copeptin. Postepy Dermatol Alergol 2019; 36(5): 609-15.
[http://dx.doi.org/10.5114/ada.2019.89509] [PMID: 31839779]
[28]
Lee YB, Lee SY, Choi JY, et al. Incidence, prevalence, and mortality of Adamantiades-Behçet’s disease in Korea: A nationwide, population-based study (2006-2015). J Eur Acad Dermatol Venereol 2018; 32(6): 999-1003.
[http://dx.doi.org/10.1111/jdv.14601] [PMID: 28940547]
[29]
Menter MA, Mehta N, Lebwohl M, et al. The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: Post hoc analysis of two phase 3 trials (ReSURFACE 1 and ReSURFACE 2). J Drugs Dermatol 2020; 19(8): 703-8.
[http://dx.doi.org/10.36849/JDD.2020.5337] [PMID: 32845115]
[30]
Kolar P. Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data. J Ophthalmol 2014; 2014: 1-5.
[http://dx.doi.org/10.1155/2014/724780] [PMID: 25009743]
[31]
Muhammad FY, Peters K, Wang D, Lee DJ. Exacerbation of autoimmune uveitis by obesity occurs through the melanocortin 5 receptor. J Leukoc Biol 2019; 106(4): 879-87.
[http://dx.doi.org/10.1002/JLB.MA0119-030RR] [PMID: 31287586]
[32]
Mamo JG. The rate of visual loss in Behçet’s disease. Arch Ophthalmol 1970; 84(4): 451-2.
[http://dx.doi.org/10.1001/archopht.1970.00990040453009] [PMID: 5492449]
[33]
Muhaya M, Lightman S, Ikeda E, et al. Behçet’s disease in Japan and in Great Britain: A comparative study. Ocul Immunol Inflamm 2000; 8(3): 141-8.
[http://dx.doi.org/10.1076/0927-3948(200009)831-KFT141] [PMID: 11120575]
[34]
Abd El Latif E, Abdel Kader Fouly Galal M, Tawfik MA, Elmoddather M, Nooreldin A, Shamselden Yousef H. Pattern of uveitis associated with Behçet’s disease in an Egyptian cohort. Clin Ophthalmol 2020; 14: 4005-14.
[http://dx.doi.org/10.2147/OPTH.S287298] [PMID: 33262566]
[35]
Hu Y, Zhu Y, Lian N, Chen M, Bartke A, Yuan R. Metabolic syndrome and skin diseases. Front Endocrinol (Lausanne) 2019; 10: 788.
[http://dx.doi.org/10.3389/fendo.2019.00788] [PMID: 31824416]
[36]
Seremet S, Gurel MS. Miscellaneous skin disease and the metabolic syndrome. Clin Dermatol 2018; 36(1): 94-100.
[http://dx.doi.org/10.1016/j.clindermatol.2017.09.016] [PMID: 29241760]
[37]
Abdollahian T, Pourzare Mehrbani S, Motahari P. The relationship between recurrent aphthous stomatitis and metabolic syndrome. Adv Biosci Clin Med 2020; 8(4): 8-11.
[http://dx.doi.org/10.7575/aiac.abcmed.v.8n.4p.8]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy